Nicotinic agonists, considered within the context of raw materials, are a class of drugs specifically designed to selectively bind to and activate nicotinic acetylcholine receptors (nAChRs) present in the central nervous system (CNS), peripheral nervous system (PNS), and various tissues. These receptors play a pivotal role in mediating the effects of the neurotransmitter acetylcholine. When a nicotinic agonist binds to these receptors, it replicates the actions of acetylcholine, triggering a diverse range of physiological and pharmacological responses. Activation of nicotinic receptors prompts the release of neurotransmitters, including dopamine, serotonin, norepinephrine, and gamma-aminobutyric acid (GABA), leading to varied effects based on receptor subtypes and their bodily locations. In the CNS, nicotinic agonists demonstrate the potential to enhance cognitive function, attention, and memory, making them subjects of research for treating cognitive disorders like Alzheimer's and attention deficit hyperactivity disorder (ADHD). In the PNS, nicotinic agonists stimulate neurotransmitter and hormone release, resulting in muscle contraction, increased heart rate, and elevated blood pressure. These properties make them valuable in medicine for diverse applications, including use as muscle relaxants, smoking cessation aids, and treatments for conditions such as myasthenia gravis. Nicotinic agonists, with various subtypes based on receptor selectivity, encompass examples like nicotine (from tobacco), varenicline (for smoking cessation), and drugs like carbachol and pilocarpine (affecting the PNS). It is crucial to recognize that while some nicotinic agonists have therapeutic applications, nicotine itself, when derived from tobacco or used recreationally, can be addictive and pose health risks. Therefore, the use of nicotinic agonists should be under the guidance and supervision of healthcare professionals.